CELLBIXAN Trademark

Trademark Overview

On Friday, September 26, 2008, a trademark application was filed for CELLBIXAN with the United States Patent and Trademark Office. The USPTO has given the CELLBIXAN trademark a serial number of 79062084. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Wednesday, September 26, 2018. This trademark is owned by Laboratoire Français; du Fractionnementet des Biotechnologies. The CELLBIXAN trademark is filed in the Pharmaceutical Products category with the following description:

Recombinant monoclonal antibody directed against CD 20, for disease testing and medical treatment use
cellbixan

General Information

Serial Number79062084
Word MarkCELLBIXAN
Filing DateFriday, September 26, 2008
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateWednesday, September 26, 2018
Registration Number3643871
Registration DateTuesday, June 23, 2009
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 7, 2009

Trademark Statements

Goods and ServicesRecombinant monoclonal antibody directed against CD 20, for disease testing and medical treatment use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, January 29, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLaboratoire Français; du Fractionnementet des Biotechnologies
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressF-91940 Les Ulis
FR
Party NameLaboratoire Français; du Fractionnementet des Biotechnologies
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressF-91940 Les Ulis
FR
Party NameLaboratoire Français; du Fractionnementet des Biotechnologies
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressF-91940 Les Ulis
FR

Trademark Events

Event DateEvent Description
Friday, April 26, 2019NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Friday, April 26, 2019DEATH OF INTERNATIONAL REGISTRATION
Friday, March 24, 2017TOTAL INVALIDATION PROCESSED BY THE IB
Friday, September 30, 2016GENERIC MADRID TRANSACTION SENT TO IB
Friday, September 30, 2016GENERIC MADRID TRANSACTION CREATED
Thursday, September 29, 2016TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, January 29, 2016CANCELLED SECTION 71
Thursday, March 26, 2015NEW REPRESENTATIVE AT IB RECEIVED
Monday, July 21, 2014NEW REPRESENTATIVE AT IB RECEIVED
Sunday, March 31, 2013FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, October 6, 2009FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, October 6, 2009FINAL DISPOSITION PROCESSED
Thursday, September 24, 2009FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, June 23, 2009REGISTERED-PRINCIPAL REGISTER
Tuesday, April 7, 2009PUBLISHED FOR OPPOSITION
Wednesday, March 18, 2009NOTICE OF PUBLICATION
Friday, February 27, 2009LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, February 27, 2009ASSIGNED TO LIE
Tuesday, February 24, 2009APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, February 23, 2009TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, February 23, 2009TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 23, 2009CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 23, 2009TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 30, 2009REFUSAL PROCESSED BY IB
Wednesday, December 31, 2008NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, December 31, 2008REFUSAL PROCESSED BY MPU
Tuesday, December 30, 2008NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, December 29, 2008NON-FINAL ACTION WRITTEN
Saturday, December 27, 2008ASSIGNED TO EXAMINER
Friday, December 19, 2008APPLICATION FILING RECEIPT MAILED
Monday, December 15, 2008NEW APPLICATION ENTERED IN TRAM
Friday, December 12, 2008SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

cellbixan testing medical treatment disease against monoclonal antibody directed recombinant